REFERENCES

CANNABIS EFFECTIVENESS PEER REVIEWED STUDIES

For a great initial review of The Literature Go To http://norml.org/index.cfm?Group_ID=7002

http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2011.01238.x/pdf

Legal Links

Educational Documents

Mar. 1, 2011
European Journal of Neurology

Aug. 30, 2010
Canadian Medical Association Journal

Nov. 6, 2009
Journal of Pain and Symptom Management

Aug. 2008
Neuropsychopharmacology
Vol. 34
Pages 672-680

June 2008
Journal of Pain
Vol. 9, Issue 6,
Pages 505-521

Mar. 2007
European Journal of Neurology
Vol. 14, No. 3,
Page 290

Feb. 13, 2007
Neurology
Vol. 68, Pages 515-521

Sep. 2005
Neurology
Vol. 65, Issue 6, Pages 812-819

Dec. 2004
Pain
Vol. 112, Issue 3, Pages 299-306

Aug. 2004
Multiple Sclerosis
Vol. 10, Issue 4, Pages 434-441

Aug. 2004
Multiple Sclerosis
Vol. 10, Issue 4, Pages 417-424

Feb. 2003
Clinical Rehabilitation
Vol. 17, Pages 18-26

Dec. 25, 2007
Journal of the National Cancer Institute
Vol. 100, Number 1, Page 51

Aug. 15, 2007
Journal of Acquired Immune Deficiency Syndromes
Vol. 45, Number 5, Pages 545-554

Feb. 2005
Journal of Neuroscience
Vol. 25 Issue 8, Pages 1904-1913

Sep. 2004
Movement Disorders
Vol. 19, Issue 9, Pages 1102-1106

Aug. 2004
Multiple Sclerosis
Vol. 10, Issue 4, Pages 425-433

Oct. 2003
Nature Reviews – Cancer
Vol. 3 Oct. 2003 pp. 745-755

Aug. 2003
Annals of Internal Medicine
Vol. 139, Issue 4, Pages 258-266

Mar. 2003
Pain
Vol. 102, Issue 1-2, Pages 211-216
Jan. 2002
Journal of Cannabis Therapeutics

Nov. 2001
International Journal of Drug Policy
Vol. 12, Issue 5-6, Pages 377-383

July 2001
Pharmacology, Biochemistry and Behavior
Vol. 69, Issue 3-4, Pages 343-350

Apr. 2001
Nature
Vol. 410, Issue 6830, Page 763

2001
Journal of Cannabis Therapeutics
Vol. 1, Issue 3/4, Pages 183-205

Dec. 1998
Acta Psychiatrica Scandinavica
Vol. 98, Issue 6, Pages 502-506

Apr. – June 1998
Journal of Psychoactive Drugs
Vol. 30, Issue 2, Pages 171-177

1997
European Neurology
Vol. 38, Issue 1, pages 44-48

July 1991
American Journal of Clinical Oncology
Vol. 9, Issue 7, Pages 1314-1319

Oct. 2005
Journal of Clinical Investigation
10.1172/JCI25509

May 2005
Nature Medicine
doi:10.1038/nm1255

Sep. 2004
Neuropharmacology
Vol. 47, Issue 3, p. 315-323

Jan. 2003
Journal of Clinical Investigation
111:43-50

Rubio M, Villain H, Docagne F, Roussel BD, Ramos JA, et al. (2011) Pharmacological Activation/Inhibition of the Cannabinoid System Affects Alcohol Withdrawal-Induced Neuronal Hypersensitivity to Excitotoxic Insults. PLoS ONE 6(8): e23690. doi:10.1371/journal.pone.0023690

FOLLOWING GROUP ARE REFERENCED FROM DR. ETHAN RUSSO:

Taming THC: potential
cannabis synergy and
phytocannabinoid-terpenoid
entourage effects

BRITISH MEDICAL JOURNAL

Bettarini F, Borgonovi GE, Fiorani T, Gagliardi I, Caprioli V,
Massardo P et al. (1993). Antiparasitic compounds from East African
plants: isolation and biological activtiry of anonaine, matricarianol,
canthin-6-one, and caryophyllene oxide. Insect Sci Appl 14: 93–99.
Bickers D, Calow P, Greim H, Haniﬁn JM, Rogers AE, Saurat JH
et al. (2003). A toxicologic and dermatologic assessment of linalool
and related esters when used as fragrance ingredients. Food Chem
Toxicol 41: 919–942.
Binet L, Binet P, Miocque M, Roux M, Bernier A (1972). Recherches
sur les proprietes pharmcodynamiques (action sedative et action
spasmolytique) de quelques alcools terpeniques aliphatiques. Ann
Pharm Fr 30: 611–616.
Biro T, Olah A, Toth BI, Czifra G, Zouboulis CC, Paus R (2009).
Cannabidiol as a novel anti-acne agent? Cannabidiol inhibits lipid
synthesis and induces cell death in human sebaceous gland-derived
sebocytes. Proceedings 19th Annual Conference on the
Cannabinoids. International Cannabinoid Research Society:
Pheasant Run, St. Charles, IL, p. 28.
Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE,
Brandi I et al. (2001). Molecular targets for cannabidiol and its
synthetic analogues: effect on vanilloid VR1 receptors and on the
cellular uptake and enzymatic hydrolysis of anandamide. Br J
Pharmacol 134: 845–852.
Bisset NG, Wichtl M (2004). Herbal Drugs and
Phytopharmaceuticals: A Handbook for Practice on A Scientiﬁc
Basis, 3rd edn. Medpharm Scientiﬁc Publishers: Stuttgart; CRC
Press: Boca Raton, FL.
Bloor RN, Wang TS, Spanel P, Smith D (2008). Ammonia release
from heated ‘street’ cannabis leaf and its potential toxic effects on
cannabis users. Addiction 103: 1671–1677.
Bohlmann J, Meyer-Gauen G, Croteau R (1998). Plant terpenoid
synthases: molecular biology and phylogenetic analysis. Proc Natl
Acad Sci USA 95: 4126–4133.
Bolognini D, Costa B, Maione S, Comelli F, Marini P, Di Marzo V
et al. (2010). The plant cannabinoid Delta9-tetrahydrocannabivarin
can decrease signs of inﬂammation and inﬂammatory pain in mice.
Br J Pharmacol 160: 677–687.
Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA,
Seal ML et al. (2008). Neural basis of Delta-9-tetrahydrocannabinol
and cannabidiol: effects during response inhibition. Biol Psychiatry
64: 966–973.
Bowles EJ (2003). The Chemistry of Aromatherapeutic Oils, 3rd
edn. Allen & Unwin: Crow’s Nest, NSW.
Bradshaw HB, Lee SH, McHugh D (2009). Orphan endogenous
lipids and orphan GPCRs: a good match. Prostaglandins Other
Lipid Mediat 89: 131–134.
Brenneisen R (2007). Chemistry and analysis of phytocannabinoids
and other Cannabis constituents. In: Elsohly M (ed.). Cannabis and
the Cannabinoids. Humana Press: Totowa, NY, pp. 17–49.
Buchbauer G (2010). Biological activities of essential oils. In:
Baser KHC, Buchbauer G (eds). Handbook of Essential Oils: Science,
Technology, and Applications. CRC Press: Boca Raton, FL,
pp. 235–280.
Buchbauer G, Jirovetz L, Jager W, Dietrich H, Plank C (1991).
Aromatherapy: evidence for sedative effects of the essential oil of
lavender after inhalation. Z Naturforsch [C] 46: 1067–1072.
Buchbauer G, Jirovetz L, Jager W, Plank C, Dietrich H (1993).
Fragrance compounds and essential oils with sedative effects upon
inhalation. J Pharm Sci 82: 660–664.
Calkins A (1871). Opium and the Opium-Appetite: with Notices of
Alcoholic Beverages, Cannabis Indica, Tobacco and Coca, and Tea
and Coffee, in Their Hygienic Aspects and Pathologic Relationships.
J.B. Lippincott: Philadelphia, PA.
Campbell WE, Gammon DW, Smith P, Abrahams M, Purves TD
(1997). Composition and antimalarial activity in vitro of the
essential oil of Tetradenia riparia. Planta Med 63: 270–272.
Carlini EA, Cunha JM (1981). Hypnotic and antiepileptic effects of
cannabidiol. J Clin Pharmacol 21 (Suppl.): 417S–427S.
Carlini EA, Karniol IG, Renault PF, Schuster CR (1974). Effects of
marihuana in laboratory animals and in man. Br J Pharmacol 50:
299–309.
Carrier EJ, Auchampach JA, Hillard CJ (2006). Inhibition of an
equilibrative nucleoside transporter by cannabidiol: a mechanism
of cannabinoid immunosuppression. Proc Natl Acad Sci USA 103:
7895–7900.
Carvalho-Freitas MI, Costa M (2002). Anxiolytic and sedative effects
of extracts and essential oil from Citrus aurantium L. Biol Pharm
Bull 25: 1629–1633.
Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG (2010).
Evidence that the plant cannabinoid cannabigerol is a highly
potent alpha2-adrenoceptor agonist and moderately potent 5HT1A
receptor antagonist. Br J Pharmacol 159: 129–141.
Cawthorne MA, Wargent E, Zaibi M, Stott C, Wright S (2007). The
CB1 antagonist, delta-9-tetrahydrocannabivarin (THCV) has antioebesity activity in dietary-induced obese (DIO) mice. Proceedings
17th Annual Symposium on the Cannabinoids. International Cannabinoid Research Society: Saint-Sauveur, QC, p. 141.
Choi HS, Song HS, Ukeda H, Sawamura M (2000).
Radical-scavenging activities of citrus essential oils and their
components: detection using 1,1-diphenyl-2-picrylhydrazyl. J Agric
Food Chem 48: 4156–4161.
Christison R (1848). A Dispensatory Or Commentary on the
Pharmacopoeias of Great Britain and the United States. Lea and
Blanchard: Philadelphia, PA.
Christison A (1851). On the natural history, action, and uses of
Indian hemp. Monthly J Med Sci Edinburgh, Scotland 13: 26–45.
117-121.
Clarke RC (2010). Hashish!, 2nd edn. Red Eye Press: Los Angeles, CA.
Comelli F, Bettoni I, Colleoni M, Giagnoni G, Costa B (2009).
Beneﬁcial effects of a Cannabis sativa extract treatment on
diabetes-induced neuropathy and oxidative stress. Phytother Res 23:
1678–1684.
Cornwell PA, Barry BW (1994). Sesquiterpene components of
volatile oils as skin penetration enhancers for the hydrophilic
permeant 5-ﬂuorouracil. J Pharm Pharmacol 46: 261–269.
Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M (2007).
The non-psychoactive cannabis constituent cannabidiol is an orally
effective therapeutic agent in rat chronic inﬂammatory and
neuropathic pain. Eur J Pharmacol 556: 75–83.
Couladis M, Ozcan M, Tzakou O, Akgul A (2003). Comparative
essential oil compostion of various parts of the turpentine tree
(Pistacia terebinthus) growing wild in Turkey. J Sci Food Agric 83:
136–138.

Crippa JA, Zuardi AW, Hallak JE (2010). [Therapeutical use of the
cannabinoids in psychiatry]. Rev Bras Psiquiatr 32 (Suppl. 1):
S56–S66.
Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran F,
Marti NSRO et al. (2011). Neural basis of anxiolytic effects of
cannabidiol (CBD) in generalized social anxiety disorder: a
preliminary report. J Psychopharmacol 25: 121–130.
Croteau R (1987). Biosynthesis and catabolism of monoterpenoids.
Chem Rev 87: 929–954.
De Oliveira AC, Ribeiro-Pinto LF, Paumgartten JR (1997). In vitro
inhibition of CYP2B1 monooxygenase by beta-myrcene and other
monoterpenoid compounds. Toxicol Lett 92: 39–46.
D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T,
Wu YT et al. (2004). The psychotomimetic effects of intravenous
delta-9-tetrahydrocannabinol in healthy individuals: implications
for psychosis. Neuropsychopharmacology 29: 1558–1572.
Davalos SD, Fournier G, Boucher F, Paris M (1977). [Contribution
to the study of Mexican marihuana. Preliminary studies:
cannabinoids and essential oil (author’s transl)]. J Pharm Belg 32:
89–99.
Davis WM, Hatoum NS (1983). Neurobehavioral actions of
cannabichromene and interactions with delta
9-tetrahydrocannabinol. Gen Pharmacol 14: 247–252.
De Oliveira AC, Ribeiro-Pinto LF, Paumgartten JR (1997). In vitro
inhibition of CYP2B1 monooxygenase by beta-myrcene and other
monoterpenoid compounds. Toxicol Lett 92: 39–46.
De Petrocellis L, Di Marzo V (2010). Non-CB1, non-CB2 receptors
for endocannabinoids, plant cannabinoids, and synthetic
cannabimimetics: focus on G-protein-coupled receptors and
transient receptor potential channels. J Neuroimmune Pharmacol 5:
103–121.
De Petrocellis L, Vellani V, Schiano-Moriello A, Marini P,
Magherini PC, Orlando P et al. (2008). Plant-derived cannabinoids
modulate the activity of transient receptor potential channels of
ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther 325:
1007–1015.
De Petrocellis L, Ligresti A, Moriello AS, Allara M, Bisogno T,
Petrosino S et al. (2011). Effects of cannabinoids and
cannabinoid-enriched Cannabis extracts on TRP channels
and endocannabinoid metabolic enzymes. Br J Pharmacol
DOI:10.1111/j.1476-5381.2010.0166.x
Delgado P, Moreno F (1999). Antidepressants and the brain. Int
Clin Psychopharmacol 14 (Suppl. 1): S9–16.
Delong GT, Wolf CE, Poklis A, Lichtman AH (2010).
Pharmacological evaluation of the natural constituent of
Cannabis sativa, cannabichromene and its modulation by
Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend 112: 126–133.
Denson TF, Earleywine M (2006). Decreased depression in
cannabis users. Addict Behav 31: 738–742.
Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC
(1988). Determination and characterization of a cannabinoid
receptor in rat brain. Mol Pharmacol 34: 605–613.
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA,
Grifﬁn G et al. (1992). Isolation and structure of a brain constituent
that binds to the cannabinoid receptor. Science 258: 1946–1949.
Deyo R, Musty R (2003). A cannabichromene (CBC) extract alters
behavioral despair on the mouse tail suspension test of depression.
Proceedings 2003 Symposium on the Cannabinoids. International
Cannabinoid Research Society: Cornwall, ON, p. 146.
Dirikoc S, Priola SA, Marella M, Zsurger N, Chabry J (2007).
Nonpsychoactive cannabidiol prevents prion accumulation and
protects neurons against prion toxicity. J Neurosci 27: 9537–9544.
Dobrosi N, Toth BI, Nagy G, Dozsa A, Geczy T, Nagy G et al. (2008).
Endocannabinoids enhance lipid synthesis and apoptosis of human
sebocytes via cannabinoid receptor-2-mediated signaling. FASEB J
22: 3685–3695.
Douthwaite AH (1947). Choice of drugs in the treatment of
duodenal ulcer. Br Med J 2: 43–47.
Dreher M (2002). Crack heads and roots daughters: the therapeutic
use of cannabis in Jamaica. J Cannabis Therap 2: 121–133.
Duru ME, Cakir A, Kordali S, Zengin H, Harmandar M, Izumi S
et al. (2003). Chemical composition and antifungal properties of
essential oils of three Pistacia species. Fitoterapia 74: 170–176.
Elisabetsky E, Marschner J, Souza DO (1995). Effects of Linalool on
glutamatergic system in the rat cerebral cortex. Neurochem Res 20:
461–465.
ElSohly HN, Turner CE, Clark AM, ElSohly MA (1982). Synthesis
and antimicrobial activities of certain cannabichromene and
cannabigerol related compounds. J Pharm Sci 71: 1319–1323.
Esposito G, De Filippis D, Carnuccio R, Izzo AA, Iuvone T (2006a).
The cannabis component cannabidiol inhibits
beta-amyloid-induced tau protein hyperphosphorylation through
Wnt/beta-catenin pathway rescue in PC12 cells. J Mol Med 84:
253–258.
Esposito G, De Filippis D, Maiuri MC, De Stefano D, Carnuccio R,
Iuvone T (2006b). Cannabidiol inhibits inducible nitric oxide
synthase protein expression and nitric oxide production in
beta-amyloid stimulated PC12 neurons through p38 MAP kinase
and NF-kappaB involvement. Neurosci Lett 399: 91–95.
Eubanks LM, Rogers CJ, Beuscher AE 4th, Koob GF, Olson AJ,
Dickerson TJ et al. (2006). A molecular link between the active
component of cannabis and Alzheimer’s disease pathology. Mol
Pharm 3: 773–777.
Evans FJ (1991). Cannabinoids: the separation of central from
peripheral effects on a structural basis. Planta Med 57: S60–S67.
Fairbairn JW, Pickens JT (1981). Activity of cannabis in relation to
its delta’-trans-tetrahydro-cannabinol content. Br J Pharmacol 72:
401–409.
Falk AA, Hagberg MT, Lof AE, Wigaeus-Hjelm EM, Wang ZP (1990).
Uptake, distribution and elimination of alpha-pinene in man after
exposure by inhalation. Scand J Work Environ Health 16: 372–378.
Falk-Filipsson A, Lof A, Hagberg M, Hjelm EW, Wang Z (1993).
d-limonene exposure to humans by inhalation: uptake,
distribution, elimination, and effects on the pulmonary function. J
Toxicol Environ Health 38: 77–88.
Fan X, Gates RA (2001). Degradation of monoterpenes in orange
juice by gamma radiation. J Agric Food Chem 49: 2422–2426.
Fan X, Sokorai KJ (2002). Changes in volatile compounds of
gamma-irradiated fresh cilantro leaves during cold storage. J Agric
Food Chem 50: 7622–7626.
Farag RS, Shalaby AS, El-Baroty GA, Ibrahim NA, Ali MA,
Hassan EM (2004). Chemical and biological evaluation of the
essential oils of different Melaleuca species. Phytother Res 18:
30–35.
Favrat B, Menetrey A, Augsburger M, Rothuizen L, Appenzeller M,
Buclin T et al. (2005). Two cases of ‘cannabis acute psychosis’
following the administration of oral cannabis. BMC Psychiatry
5: 17.

CBD and Cancer

http://www.ncbi.nlm.nih.gov/pubmed/20053780

http://www.ncbi.nlm.nih.gov/pubmed/16728591

http://www.ncbi.nlm.nih.gov/pubmed/21566064

http://www.ncbi.nlm.nih.gov/pubmed/18833429

Tumor Studies:

http://www.ncbi.nlm.nih.gov/pubmed/18035205

http://www.ncbi.nlm.nih.gov/pubmed/14617682

Clinical Trials:

http://clinicaltrials.gov/ct2/results?term=cannabidiol

http://www.cannabis-med.org/studies/ww_en_db_study_search.php

REFERENCES CITED BY GW PHARMACEUTICALS

Windholz et al., The Merck Index, Tenth Edition (1983) p. 241, abstract No. 1723.* .
Mechoulam et al., "A Total Synthesis of d1-.DELTA..sup.1 -Tetrahydrocannabinol, the Active Constituent of Hashish.sup.1," Journal of the American Chemical Society, 87:14:3273-3275 (1965). .
Mechoulam et al., "Chemical Basis of Hashish Activity," Science, 18:611-612 (1970). .
Ottersen et al., "The Crystal and Molecular Structure of Cannabidiol," Acta Chem. Scand. B 31, 9:807-812 (1977). .
Cunha et al., "Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients.sup.1," Pharmacology, 21:175-185 (1980). .
Consroe et al., "Acute and Chronic Antiepileptic Drug Effects in Audiogenic Seizure-Susceptible Rats," Experimental Neurology, Academic Press Inc., 70:626-637 (1980). .
Turkanis et al., "Electrophysiologic Properties of the Cannabinoids," J. Clin. Pharmacol., 21:449S-463S (1981). .
Carlini et al., "Hypnotic and Antielpileptic Effects of Cannabidiol," J. Clin. Pharmacol., 21:417S-427S (1981). .
Karler et al., "The Cannabinoids as Potential Antiepileptics," J. Clin. Pharmacol., 21:437S-448S (1981). .
Consroe et al., "Antiepileptic Potential of Cannabidiol Analgos," J. Clin. Pharmacol., 21:428S-436S (1981). .
Colasanti et al., "Ocular Hypotension, Ocular Toxicity,a nd Neurotoxicity in Response to Marihuana Extract and Cannabidiol," Gen Pharm., Pergamon Press Ltd., 15(6):479-484 (1984). .
Colasanti et al., "Intraocular Pressure, Ocular Toxicity and Neurotoxicity after Administration of Cannabinol or Cannabigerol," Exp. Eye Res., Academic Press Inc., 39:251-259 (1984). .
Volfe et al., "Cannabinoids Block Release of Serotonin from Platelets Induced by Plasma frm Migraine Patients," Int. J. Clin. Pharm. Res., Bioscience Ediprint Inc., 4:243-246 (1985). .
Agurell et al., "Pharmacokinetics and Metabolism of .DELTA..sup.1 -Tetrahydrocannabinol and Other Cannabinoids with Emphasis on Man*," Pharmacological Reviews, 38(1):21-43 (1986). .
Karler et al., "Different Cannabinoids Exhibit Different Pharmacological and Toxicological Properties,"NIDA Res. Monogr., 79:96-107 (1987). .
Samara et al., "Pharmacokinetics of Cannabidiol in Dogs," Drug Metabolism and Disposition, 16(3):469-472 (1988). .
Choi, "Glutamate Neurotoxicity and Diseases of the Nervous System," Neuron, Cell Press, 1:623-634 (1988). .
Eshhar et al., "Neuroprotective and Antioxidant Activities of HU-211, A Novel NMDA Receptor Antagonist," European Journal of Pharmacology, 283:19-29 (1995). .
Skaper et al., "The ALIAmide Palmitoylethanolamide and Cannabinoids, but not Anandamide, are Protective in a Delayed Postglutamate Paradigm of Excitotoxic Death in Cerebellar Granule Neurons," Neurobiology, Proc. Natl. Acad. Sci. USA, 93:3984-3989 (1996). .
Alonso et al., "Simple Synthesis of 5-Substituted Resorcinols: A Revisited Family of Interesting Bioactive Molecules," J. Org. Chem., American Chemical Society, 62(2):417-421 (1997). .
Combes et al. "A Simple Synthesis of the Natural 2,5-Dialkylresorcinol Free Radical Scavenger Antioxidant: Resorstation," Synthetic Communications, Marcel Dekker, Inc., 27(21):3769-3778 (1997). .
Shohami et al., "Oxidative Stress in Closed-Head Injury: Brain Antioxidant Capacity as an Indicator of Functional Outcome," Journal of Cerebral Blood Flow and Metabolism, Lippincott-Raven Publishers, 17(10):1007-1019 (1997). .
Zurier et al., "Dimethylheptyl-THC-11 OIC Acid," Arthritis & Rheumatism, 41(1):163-170 (1998). .
Hampson et al., "Dual Effects of Anandamide on NMDA Receptor-Mediated Responses and Neurotransmission," Journal of Neurochemistry, Lippincott-Raven Publishers, 70(2):671-676 (1998). .
Hampson et al., "Cannabidiol and (-).DELTA..sup.9 -tetrahydrocannabiono are Neuroprotective Antioxidants," Medical Sciences, Proc. Natl. Acad. Sci. USA, 8268-8273 (1998)..

Windholz et al., The Merck Index, Tenth Edition (1983) p. 241, abstract No. 1723.* .
Mechoulam et al., "A Total Synthesis of d1-.DELTA..sup.1 -Tetrahydrocannabinol, the Active Constituent of Hashish.sup.1," Journal of the American Chemical Society, 87:14:3273-3275 (1965). .
Mechoulam et al., "Chemical Basis of Hashish Activity," Science, 18:611-612 (1970). .
Ottersen et al., "The Crystal and Molecular Structure of Cannabidiol," Acta Chem. Scand. B 31, 9:807-812 (1977). .
Cunha et al., "Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients.sup.1," Pharmacology, 21:175-185 (1980). .
Consroe et al., "Acute and Chronic Antiepileptic Drug Effects in Audiogenic Seizure-Susceptible Rats," Experimental Neurology, Academic Press Inc., 70:626-637 (1980). .
Turkanis et al., "Electrophysiologic Properties of the Cannabinoids," J. Clin. Pharmacol., 21:449S-463S (1981). .
Carlini et al., "Hypnotic and Antielpileptic Effects of Cannabidiol," J. Clin. Pharmacol., 21:417S-427S (1981). .
Karler et al., "The Cannabinoids as Potential Antiepileptics," J. Clin. Pharmacol., 21:437S-448S (1981). .
Consroe et al., "Antiepileptic Potential of Cannabidiol Analgos," J. Clin. Pharmacol., 21:428S-436S (1981). .
Colasanti et al., "Ocular Hypotension, Ocular Toxicity,a nd Neurotoxicity in Response to Marihuana Extract and Cannabidiol," Gen Pharm., Pergamon Press Ltd., 15(6):479-484 (1984). .
Colasanti et al., "Intraocular Pressure, Ocular Toxicity and Neurotoxicity after Administration of Cannabinol or Cannabigerol," Exp. Eye Res., Academic Press Inc., 39:251-259 (1984). .
Volfe et al., "Cannabinoids Block Release of Serotonin from Platelets Induced by Plasma frm Migraine Patients," Int. J. Clin. Pharm. Res., Bioscience Ediprint Inc., 4:243-246 (1985). .
Agurell et al., "Pharmacokinetics and Metabolism of .DELTA..sup.1 -Tetrahydrocannabinol and Other Cannabinoids with Emphasis on Man*," Pharmacological Reviews, 38(1):21-43 (1986). .
Karler et al., "Different Cannabinoids Exhibit Different Pharmacological and Toxicological Properties,"NIDA Res. Monogr., 79:96-107 (1987). .
Samara et al., "Pharmacokinetics of Cannabidiol in Dogs," Drug Metabolism and Disposition, 16(3):469-472 (1988). .
Choi, "Glutamate Neurotoxicity and Diseases of the Nervous System," Neuron, Cell Press, 1:623-634 (1988). .
Eshhar et al., "Neuroprotective and Antioxidant Activities of HU-211, A Novel NMDA Receptor Antagonist," European Journal of Pharmacology, 283:19-29 (1995). .
Skaper et al., "The ALIAmide Palmitoylethanolamide and Cannabinoids, but not Anandamide, are Protective in a Delayed Postglutamate Paradigm of Excitotoxic Death in Cerebellar Granule Neurons," Neurobiology, Proc. Natl. Acad. Sci. USA, 93:3984-3989 (1996). .
Alonso et al., "Simple Synthesis of 5-Substituted Resorcinols: A Revisited Family of Interesting Bioactive Molecules," J. Org. Chem., American Chemical Society, 62(2):417-421 (1997). .
Combes et al. "A Simple Synthesis of the Natural 2,5-Dialkylresorcinol Free Radical Scavenger Antioxidant: Resorstation," Synthetic Communications, Marcel Dekker, Inc., 27(21):3769-3778 (1997). .
Shohami et al., "Oxidative Stress in Closed-Head Injury: Brain Antioxidant Capacity as an Indicator of Functional Outcome," Journal of Cerebral Blood Flow and Metabolism, Lippincott-Raven Publishers, 17(10):1007-1019 (1997). .
Zurier et al., "Dimethylheptyl-THC-11 OIC Acid," Arthritis & Rheumatism, 41(1):163-170 (1998). .
Hampson et al., "Dual Effects of Anandamide on NMDA Receptor-Mediated Responses and Neurotransmission," Journal of Neurochemistry, Lippincott-Raven Publishers, 70(2):671-676 (1998). .
Hampson et al., "Cannabidiol and (-).DELTA..sup.9 -tetrahydrocannabiono are Neuroprotective Antioxidants," Medical Sciences, Proc. Natl. Acad. Sci. USA, 8268-8273 (1998)..

http://www.cannabis-med.org/studies/study.php

Don't Get High….. Get Well

REFERENCES